IGM Biosciences
IGMS
IGMS was delisted on the 13th of August, 2025.
89 hedge funds and large institutions have $316M invested in IGM Biosciences in 2022 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 31 increasing their positions, 26 reducing their positions, and 19 closing their positions.
695% more call options, than puts
Call options by funds: $2M | Put options by funds: $252K
19% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 26
4% less funds holding
Funds holding: 93 → 89 (-4)
6.23% less ownership
Funds ownership: 70.11% → 63.87% (-6.2%)
11% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 19
35% less capital invested
Capital invested by funds: $487M → $316M (-$172M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$6.72M |
| 2 |
Millennium Management
New York
|
+$6.56M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$3.47M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$1.26M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
+$1.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$10.8M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$7.98M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$5.69M |
| 4 |
Goldman Sachs
New York
|
-$4.09M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$3.62M |
IGMS Hedge Fund Activity: Q2 2022 in Review
89 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in IGM Biosciences (IGMS) for Q2 2022, worth a combined $316M — down 35% from $487M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of IGMS and 17 opened new positions — a net loss of 2 holders — while 26 trimmed existing stakes and 31 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $6.72M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $10.8M sold.
- 89 institutional investors held IGM Biosciences (IGMS) as of Q2 2022, down from 93 in Q1 2022.
- Funds reported $316M of IGM Biosciences stock for Q2 2022, down 35% quarter-over-quarter.
- 17 funds opened new IGM Biosciences positions in Q2 2022 and 19 closed out, a net change of -2 holders.
- The largest IGM Biosciences buyer in Q2 2022 was T. Rowe Price Associates, an estimated $6.72M added.
- The largest IGM Biosciences seller in Q2 2022 was Cormorant Asset Management, an estimated $10.8M sold.
Based on aggregated 13F filings for Q2 2022.